Proposed Data Collection Submitted for Public Comment and Recommendations, 48146-48147 [2021-18541]

Download as PDF 48146 Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices ESTIMATED ANNUALIZED BURDEN HOURS Form name Health care providers ...................................... Study screener ............................................... Web-based survey ......................................... Exploratory Guide—Prevention with Positives In-depth Interview. Exploratory Guide—Patient Centered Care In-depth Interview. Exploratory Guide—HIV Prevention In-depth Interview. Message Testing In-depth Interview Guide ... Concept Testing In-depth Interview Guide .... Materials Testing In-depth Interview .............. Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2021–18540 Filed 8–26–21; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [60Day–21–0600; Docket No. CDC–2021– 0087] Proposed Data Collection Submitted for Public Comment and Recommendations Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: ACTION: Notice with comment period. The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis Susceptibility Testing information collection. CDC is requesting a threeyear approval for revision to the previously approved project used to monitor and evaluate performances and practices among national laboratories for M. tuberculosis susceptibility testing. SUMMARY: lotter on DSK11XQN23PROD with NOTICES1 Number of respondents Type of respondent VerDate Sep<11>2014 17:52 Aug 26, 2021 Jkt 253001 CDC must receive written comments on or before October 26, 2021. DATES: You may submit comments, identified by Docket No. CDC–2021– 0087 by any of the following methods: • Federal eRulemaking Portal: Regulations.gov. Follow the instructions for submitting comments. • Mail: Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS–D74, Atlanta, Georgia 30329. Instructions: All submissions received must include the agency name and Docket Number. CDC will post, without change, all relevant comments to Regulations.gov. Please note: Submit all comments through the Federal eRulemaking portal (regulations.gov) or by U.S. mail to the address listed above. FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the information collection plan and instruments, contact Jeffrey M. Zirger, Information Collection Review Office, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS– D74, Atlanta, Georgia 30329; phone: 404–639–7570; Email: omb@cdc.gov. SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. In addition, the PRA also requires Federal agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information, including each new proposed collection, each proposed extension of existing collection of information, and each reinstatement of previously approved information collection before submitting the ADDRESSES: PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 Number of responses per respondent Average burden per response (in hours) 1,138 569 95 1 1 1 10/60 15/60 1 95 1 1 95 1 1 95 95 95 1 1 1 1 1 1 collection to the OMB for approval. To comply with this requirement, we are publishing this notice of a proposed data collection as described below. The OMB is particularly interested in comments that will help: 1. Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; 2. Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; 3. Enhance the quality, utility, and clarity of the information to be collected; 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses; and 5. Assess information collection costs. Proposed Project CDC Model Performance Evaluation Program (MPEP) for Mycobacterium tuberculosis Susceptibility testing (OMB Control No. 0920–0600, Exp. 2/20/ 2022)—Revision—National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC). Background and Brief Description The Centers for Disease Control and Prevention (CDC) is requesting a revision to approved information collection from participants in the CDC Model Performance for Mycobacterium tuberculosis Drug Susceptibility Testing Program for a period of three years. Revision of this information will not E:\FR\FM\27AUN1.SGM 27AUN1 48147 Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices Participants in this program include domestic clinical and public health laboratories. Data collection from laboratory participants occurs twice per year. The data collected in this program will include the susceptibility test results of primary and secondary drugs, drug concentrations, and test methods performed by laboratories on a set of performance evaluation (PE) isolates. The PE isolates are sent to participants twice a year, and participants also report demographic data such as laboratory type and the number of drug susceptibility tests performed annually. CDC requests approval for an estimated 129 burden hours annually. There is no cost to respondents to participate other than their time. for Mycobacterium tuberculosis susceptibility testing is used to monitor and evaluate performance and practices among US laboratories performing M. tuberculosis susceptibility testing. Participation in this program is one way laboratories can ensure high-quality laboratory testing, resulting in accurate and reliable testing results. By providing an evaluation program to assess the ability of laboratories to test for drug resistant M. tuberculosis strains, CDC gives laboratories a selfassessment tool to aid in optimizing their skills in susceptibility testing. The information obtained from the laboratories on susceptibility practices and procedures is used to establish variables related to good performance, assess training needs, and aid with the development of practice standards. require changes in the scope of the project. This Revision includes; (a) modification of the Instructions to Participants Letter; (b) modification of the MPEP Mycobacterium tuberculosis Results Worksheet; (c) modification of online data collection instrument; (d) modification of the MPEP Mycobacterium tuberculosis Minimum Inhibitory Concentration Results Worksheet; (e) removal of Reminder Telephone Script; and (f) modification of Aggregate Report Letter. While the overall number of cases of TB in the U.S. has decreased, rates still remain high among foreign-born persons, corrections, homeless populations, and individuals infected with HIV in major metropolitan areas. To reach the goal of eliminating TB, the Model Performance Evaluation Program ESTIMATED ANNUALIZED BURDEN HOURS Form name Domestic Laboratory ..... Participant Biosafety Compliance Letter of Agreement. MPEP Mycobacterium tuberculosis Results Worksheet. Online Survey Instrument .................................... MPEP Mycobacterium tuberculosis Minimum Inhibitory Concentration Results Form. Total ........................ .............................................................................. Jeffrey M. Zirger, Lead, Information Collection Review Office, Office of Scientific Integrity, Office of Science, Centers for Disease Control and Prevention. [FR Doc. 2021–18541 Filed 8–26–21; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Board of Scientific Counselors, National Center for Health Statistics (BSC, NCHS) Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). AGENCY: lotter on DSK11XQN23PROD with NOTICES1 ACTION: Notice of meeting. In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, National Center for Health Statistics BSC, NCHS). This meeting is open to the public. SUMMARY: VerDate Sep<11>2014 17:52 Aug 26, 2021 Jkt 253001 Number of responses per respondent Number of respondents Type of respondents 1 5/60 7 80 2 30/60 80 80 4 2 2 15/60 15/60 40 2 ........................ ........................ ........................ 129 The meeting will be held on October 22, 2021, from 11:00 a.m. to 5:30 p.m., EDT. ADDRESSES: Instructions to access the meeting are posted on the BSC website: https://www.cdc.gov/nchs/about/bsc/ bsc_meetings.htm. FOR FURTHER INFORMATION CONTACT: Rebecca Hines, M.H.S., Executive Secretary, NCHS/CDC, Board of Scientific Counselors, 3311 Toledo Road, Room 2627, Hyattsville, Maryland 20782, Telephone: (301) 458–4717; Email: RSHines@cdc.gov. SUPPLEMENTARY INFORMATION: Purpose: The Board is charged with providing advice and making recommendations to the Secretary, Department of Health and Human Services; the Director, CDC; and the Director, NCHS, regarding the scientific and technical program goals and objectives, strategies, and priorities of NCHS. Matters To Be Considered: The meeting agenda includes welcome remarks and a Center update by the NCHS Director; updates on Data Modernization (DMI), including Epidemiology and Laboratory Capacity Frm 00034 Fmt 4703 Total burden (in hours) 80 DATES: PO 00000 Average burden per response (in hours) Sfmt 4703 for Prevention and Control of Emerging Infectious Diseases (ELC) Collaboration; an update on the National Center for Health Statistics Strategic Planning; presentation on the NCHS Health Equity Strategy; updates on using the National Health Interview Survey (NHIS) as a platform for additional data collection; and an update on several NCHS Programs. Agenda items are subject to change as priorities dictate. Meeting Information: Please visit the BSC website: https://www.cdc.gov/nchs/ about/bsc/bsc_meetings.htm for more information on the meeting agenda, including instructions for accessing the live meeting broadcast. The Board will reserve time for public comment at the end of the day. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and E:\FR\FM\27AUN1.SGM 27AUN1

Agencies

[Federal Register Volume 86, Number 164 (Friday, August 27, 2021)]
[Notices]
[Pages 48146-48147]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-18541]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60Day-21-0600; Docket No. CDC-2021-0087]


Proposed Data Collection Submitted for Public Comment and 
Recommendations

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (HHS).

ACTION: Notice with comment period.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), as part 
of its continuing effort to reduce public burden and maximize the 
utility of government information, invites the general public and other 
Federal agencies the opportunity to comment on a proposed and/or 
continuing information collection, as required by the Paperwork 
Reduction Act of 1995. This notice invites comment on a proposed 
information collection project titled CDC Model Performance Evaluation 
Program (MPEP) for Mycobacterium tuberculosis Susceptibility Testing 
information collection. CDC is requesting a three-year approval for 
revision to the previously approved project used to monitor and 
evaluate performances and practices among national laboratories for M. 
tuberculosis susceptibility testing.

DATES: CDC must receive written comments on or before October 26, 2021.

ADDRESSES: You may submit comments, identified by Docket No. CDC-2021-
0087 by any of the following methods:
     Federal eRulemaking Portal: Regulations.gov. Follow the 
instructions for submitting comments.
     Mail: Jeffrey M. Zirger, Information Collection Review 
Office, Centers for Disease Control and Prevention, 1600 Clifton Road 
NE, MS-D74, Atlanta, Georgia 30329.
    Instructions: All submissions received must include the agency name 
and Docket Number. CDC will post, without change, all relevant comments 
to Regulations.gov.
    Please note: Submit all comments through the Federal eRulemaking 
portal (regulations.gov) or by U.S. mail to the address listed above.

FOR FURTHER INFORMATION CONTACT: To request more information on the 
proposed project or to obtain a copy of the information collection plan 
and instruments, contact Jeffrey M. Zirger, Information Collection 
Review Office, Centers for Disease Control and Prevention, 1600 Clifton 
Road NE, MS-D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: 
[email protected].

SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995 
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from 
the Office of Management and Budget (OMB) for each collection of 
information they conduct or sponsor. In addition, the PRA also requires 
Federal agencies to provide a 60-day notice in the Federal Register 
concerning each proposed collection of information, including each new 
proposed collection, each proposed extension of existing collection of 
information, and each reinstatement of previously approved information 
collection before submitting the collection to the OMB for approval. To 
comply with this requirement, we are publishing this notice of a 
proposed data collection as described below.
    The OMB is particularly interested in comments that will help:
    1. Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    2. Evaluate the accuracy of the agency's estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    3. Enhance the quality, utility, and clarity of the information to 
be collected;
    4. Minimize the burden of the collection of information on those 
who are to respond, including through the use of appropriate automated, 
electronic, mechanical, or other technological collection techniques or 
other forms of information technology, e.g., permitting electronic 
submissions of responses; and
    5. Assess information collection costs.

Proposed Project

    CDC Model Performance Evaluation Program (MPEP) for Mycobacterium 
tuberculosis Susceptibility testing (OMB Control No. 0920-0600, Exp. 2/
20/2022)--Revision--National Center for HIV/AIDS, Viral Hepatitis, STD, 
and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention 
(CDC).

Background and Brief Description

    The Centers for Disease Control and Prevention (CDC) is requesting 
a revision to approved information collection from participants in the 
CDC Model Performance for Mycobacterium tuberculosis Drug 
Susceptibility Testing Program for a period of three years. Revision of 
this information will not

[[Page 48147]]

require changes in the scope of the project. This Revision includes; 
(a) modification of the Instructions to Participants Letter; (b) 
modification of the MPEP Mycobacterium tuberculosis Results Worksheet; 
(c) modification of online data collection instrument; (d) modification 
of the MPEP Mycobacterium tuberculosis Minimum Inhibitory Concentration 
Results Worksheet; (e) removal of Reminder Telephone Script; and (f) 
modification of Aggregate Report Letter.
    While the overall number of cases of TB in the U.S. has decreased, 
rates still remain high among foreign-born persons, corrections, 
homeless populations, and individuals infected with HIV in major 
metropolitan areas. To reach the goal of eliminating TB, the Model 
Performance Evaluation Program for Mycobacterium tuberculosis 
susceptibility testing is used to monitor and evaluate performance and 
practices among US laboratories performing M. tuberculosis 
susceptibility testing. Participation in this program is one way 
laboratories can ensure high-quality laboratory testing, resulting in 
accurate and reliable testing results.
    By providing an evaluation program to assess the ability of 
laboratories to test for drug resistant M. tuberculosis strains, CDC 
gives laboratories a self-assessment tool to aid in optimizing their 
skills in susceptibility testing. The information obtained from the 
laboratories on susceptibility practices and procedures is used to 
establish variables related to good performance, assess training needs, 
and aid with the development of practice standards.
    Participants in this program include domestic clinical and public 
health laboratories. Data collection from laboratory participants 
occurs twice per year. The data collected in this program will include 
the susceptibility test results of primary and secondary drugs, drug 
concentrations, and test methods performed by laboratories on a set of 
performance evaluation (PE) isolates. The PE isolates are sent to 
participants twice a year, and participants also report demographic 
data such as laboratory type and the number of drug susceptibility 
tests performed annually.
    CDC requests approval for an estimated 129 burden hours annually. 
There is no cost to respondents to participate other than their time.

                                                            Estimated Annualized Burden Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                             Number of    Average burden
              Type of respondents                               Form name                    Number of     responses per   per response    Total burden
                                                                                            respondents     respondent      (in hours)      (in hours)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Domestic Laboratory............................  Participant Biosafety Compliance Letter              80               1            5/60               7
                                                  of Agreement.
                                                 MPEP Mycobacterium tuberculosis Results              80               2           30/60              80
                                                  Worksheet.
                                                 Online Survey Instrument...............              80               2           15/60              40
                                                 MPEP Mycobacterium tuberculosis Minimum               4               2           15/60               2
                                                  Inhibitory Concentration Results Form.
                                                                                         ---------------------------------------------------------------
    Total......................................  .......................................  ..............  ..............  ..............             129
--------------------------------------------------------------------------------------------------------------------------------------------------------


Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific 
Integrity, Office of Science, Centers for Disease Control and 
Prevention.
[FR Doc. 2021-18541 Filed 8-26-21; 8:45 am]
BILLING CODE 4163-18-P